Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Operating Income (2019 - 2025)

Historic Operating Income for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$188.8 million.

  • Avidity Biosciences' Operating Income fell 9239.61% to -$188.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$612.5 million, marking a year-over-year decrease of 8862.76%. This contributed to the annual value of -$378.9 million for FY2024, which is 6084.01% down from last year.
  • Per Avidity Biosciences' latest filing, its Operating Income stood at -$188.8 million for Q3 2025, which was down 9239.61% from -$171.1 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Operating Income registered a high of -$23.9 million during Q1 2021, and its lowest value of -$188.8 million during Q3 2025.
  • For the 5-year period, Avidity Biosciences' Operating Income averaged around -$73.8 million, with its median value being -$57.6 million (2023).
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 28791.87% in 2021, then crashed by 1368.28% in 2023.
  • Over the past 5 years, Avidity Biosciences' Operating Income (Quarter) stood at -$38.5 million in 2021, then tumbled by 38.08% to -$53.2 million in 2022, then fell by 25.4% to -$66.7 million in 2023, then crashed by 81.28% to -$121.0 million in 2024, then crashed by 56.05% to -$188.8 million in 2025.
  • Its last three reported values are -$188.8 million in Q3 2025, -$171.1 million for Q2 2025, and -$131.5 million during Q1 2025.